ArticleEuropean child & adolescent psychiatry2026
Multicenter retrospective study on perceived effectiveness, reported side effects, and cognitive outcomes of SSRIs in 22q11.2 deletion syndrome.
Article in European child & adolescent psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- SSRI-associated cognitive stability and psychosis risk in 22q11.2 deletion syndrome.European child & adolescent psychiatry · 2026Article
Corrections and comments
- Update of
Authors and funding
26 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
22q11.2 deletion syndrome (22q11DS) markedly increases risk of psychiatric disorders, including anxiety and mood disorders, and is associated with a spectrum of cognitive impairment, from borderline functioning to intellectual disability, with cognitive decline frequently reported. Despite widespread use of selective serotonin reuptake inhibitors (SSRIs) in 22q11DS, evidence regarding their safety, effectiveness, and potential effects on cognitive trajectories remains limited. We conducted a retrospective, observational multicenter study across nine international centers, including cross-sectional and longitudinal analyses. In the cross-sectional sample of 190 SSRI-treated individuals with 22q11DS (6-56 years), retrospective data on SSRI type, indication, perceived effectiveness, and side effects were analyzed descriptively (40-190 cases across variables). In the longitudinal analyses, intellectual quotient (IQ) trajectories were compared between 101 SSRI-treated and 213 SSRI-untreated participants (4-34 years) using mixed-model regression analyses. SSRIs were mainly prescribed for mood and/or anxiety disorders (94%) and were rated as overall effective in 71% of cases with available data, with side effects reported in 25%. SSRI-treated participants exhibited stable or modestly increasing IQ trajectories, whereas SSRI-untreated participants showed decreasing trajectories over time. In exploratory analyses, concomitant psychostimulant treatment was associated with the most favorable IQ trajectories. Treatment duration, but not dosage, was positively associated with IQ change. These findings suggest that the effects of SSRI treatment in individuals with 22q11DS may extend beyond symptom management. Controlled prospective studies are needed to confirm these findings and determine underlying mechanisms.
Indexed as
Identifiers
42565881What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.